{
  "docId": "019de070-3b27-7318-9c92-a5817b78bd41",
  "docSlug": "ce86c4a3bf509aea21f24e2159890cb6",
  "documentTitle": "BioNTech | Results Presentation Deck | 28 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 28,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "other",
  "function": "illustrate_case",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "FIH = First-in-human; CPI = Checkpoint Inhibitor; ES-SCLC = Extensive-stage small cell lung cancer.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-3b27-7318-9c92-a5817b78bd41/16",
  "deckHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41",
  "deckJsonHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41.json",
  "deckAnchorHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.9,
        "x": 0.07,
        "y": 0.18
      },
      "kind": "list",
      "text": "BNT411 is an intravenously administered small molecule TLR7 agonist; Engineered for high potency; Activation of adaptive/innate immune system; Type 1 interferon release; Potential in solid tumors; Trial initiated July 2020",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a6763aa5-a2c6-4c68-b6de-dd057749198c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.85,
        "x": 0.1,
        "y": 0.65
      },
      "kind": "subtitle",
      "text": "Study design: Phase 1/2a, first-in-human, open-label, dose-escalation trial; Evaluation of safety, PK, PD, and efficacy; Enrollment: ~60 participants",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94884336-9783-4602-860c-d3a49bae4c11",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.07,
        "y": 0.09
      },
      "kind": "title",
      "text": "BNT411: initiated FIH Phase 1 trial for our TLR7 agonist in July 2020",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "17810bf1-ab33-4397-a66d-af1fd1a55dfb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "a8d2b309-17f4-4c46-8286-0149c1d93c03",
      "evidence": "BNT411 is an intravenously administered small molecule TLR7 agonist",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 11,
      "beatId": "a7d0d755-e358-49e1-888b-58ab156af58d",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The presentation provides updates on the company's pipeline and progress in various trials",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}